Responsible Approach to Pricing
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. That’s why we consider the economic and social value of our medicines and the clinical and economic burden of diseases in our approach to pricing.
2020 Pricing Actions:
Since 2018, the average net price for Amgen medicines has declined and, for 2020, we expect a trend towards a mid-single digit decline in net price across our global portfolio of products as compared to 2019. The average list price increase across Amgen’s entire U.S. portfolio of products is in line with inflation and key pricing indices.